1. Home
  2. JEF vs ITCI Comparison

JEF vs ITCI Comparison

Compare JEF & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JEF
  • ITCI
  • Stock Information
  • Founded
  • JEF 1968
  • ITCI 2002
  • Country
  • JEF United States
  • ITCI United States
  • Employees
  • JEF N/A
  • ITCI N/A
  • Industry
  • JEF Investment Bankers/Brokers/Service
  • ITCI Biotechnology: Pharmaceutical Preparations
  • Sector
  • JEF Finance
  • ITCI Health Care
  • Exchange
  • JEF Nasdaq
  • ITCI Nasdaq
  • Market Cap
  • JEF 11.8B
  • ITCI 13.5B
  • IPO Year
  • JEF N/A
  • ITCI N/A
  • Fundamental
  • Price
  • JEF $65.62
  • ITCI $128.60
  • Analyst Decision
  • JEF Strong Buy
  • ITCI Buy
  • Analyst Count
  • JEF 3
  • ITCI 13
  • Target Price
  • JEF $81.67
  • ITCI $103.92
  • AVG Volume (30 Days)
  • JEF 1.3M
  • ITCI 2.2M
  • Earning Date
  • JEF 03-26-2025
  • ITCI 02-21-2025
  • Dividend Yield
  • JEF 2.14%
  • ITCI N/A
  • EPS Growth
  • JEF 171.82
  • ITCI N/A
  • EPS
  • JEF 2.99
  • ITCI N/A
  • Revenue
  • JEF $7,010,603,000.00
  • ITCI $613,728,000.00
  • Revenue This Year
  • JEF $17.38
  • ITCI $48.28
  • Revenue Next Year
  • JEF $12.04
  • ITCI $37.34
  • P/E Ratio
  • JEF $21.87
  • ITCI N/A
  • Revenue Growth
  • JEF 49.15
  • ITCI 46.08
  • 52 Week Low
  • JEF $40.72
  • ITCI $63.30
  • 52 Week High
  • JEF $82.68
  • ITCI $128.77
  • Technical
  • Relative Strength Index (RSI)
  • JEF 27.48
  • ITCI 83.90
  • Support Level
  • JEF $70.19
  • ITCI $126.88
  • Resistance Level
  • JEF $72.20
  • ITCI $128.19
  • Average True Range (ATR)
  • JEF 1.96
  • ITCI 0.41
  • MACD
  • JEF -0.80
  • ITCI -1.30
  • Stochastic Oscillator
  • JEF 5.35
  • ITCI 91.01

About JEF Jefferies Financial Group Inc.

Jefferies Financial Group Inc is a diversified financial services company. It has two reportable segments; Investment Banking and Capital Markets which is also the majority revenue generating segment, includes securities, commodities, corporate lending, futures and foreign exchange capital markets activities and its investment banking business, which provides underwriting and financial advisory services to clients across different sectors. The Asset Management reportable business segment provides alternative investment management services to investors in the U.S. and overseas and generates investment income from capital invested in and managed by it or its affiliated asset managers.

About ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Share on Social Networks: